These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 25432811)

  • 41. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Uniform MDT (U-MDT) regimen for all leprosy patients--another example of wishful thinking.
    Ji B; Saunderson P
    Lepr Rev; 2003 Mar; 74(1):2-6. PubMed ID: 12669926
    [No Abstract]   [Full Text] [Related]  

  • 43. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
    Mane I; Cartel JL; Grosset JH
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is drug-resistant Mycobacterium leprae a real cause for concern?: First approach to molecular monitoring of multibacillary Colombian patients with and without previous leprosy treatment.
    Guerrero MI; Colorado CL; Torres JF; León CI
    Biomedica; 2014 Apr; 34 Suppl 1():137-47. PubMed ID: 24968045
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases.
    Kundu SK; Hazra SK; Chaudhury S; Chatterjee B
    Indian J Lepr; 1984; 56(1):78-85. PubMed ID: 6548246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro and in vivo interactions of drugs used in multidrug therapy in leprosy.
    Dhople AM; Lamoureux LC; Gardner GD
    Indian J Lepr; 1991; 63(2):166-79. PubMed ID: 1664440
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New approaches to chemotherapy for leprosy.
    Waters MF
    Drugs; 1983 Dec; 26(6):465-7. PubMed ID: 6653446
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of drug regimen in lepromatous leprosy--II.
    Ramu G; Sreevatsa
    Lepr India; 1983 Apr; 55(2):200-8. PubMed ID: 6195452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Shiny red-brown papules in a 21-year-old man. Histoid leprosy.
    Aranda J; Hoang MP; Cohen JB
    Arch Dermatol; 2004 Jun; 140(6):751-6. PubMed ID: 15210473
    [No Abstract]   [Full Text] [Related]  

  • 50. [Drug resistance of Mycobacterium leprae].
    Pattyn SR
    Acta Leprol; 1986; 4(3):279-87. PubMed ID: 3551466
    [No Abstract]   [Full Text] [Related]  

  • 51. Two microbiological relapses in a patient with lepromatous leprosy.
    Chakma JK; Girdhar A; Natrajan M; Kumar A; Girdhar BK
    Lepr Rev; 2008 Sep; 79(3):331-4. PubMed ID: 19009984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.
    Penna GO; Bührer-Sékula S; Kerr LRS; Stefani MMA; Rodrigues LC; de Araújo MG; Ramos AMC; de Andrade ARC; Costa MB; Rosa PS; Gonçalves HS; Cruz R; Barreto ML; Pontes MAA; Penna MLF
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005725. PubMed ID: 28704363
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
    Matsuoka M; Kashiwabara Y; Namisato M
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A statistical analysis of two chemotherapy trials in lepromatous leprosy. I. The response to therapy as measured by inoculation of mice.
    Am J Trop Med Hyg; 1978 Sep; 27(5):1005-14. PubMed ID: 362950
    [No Abstract]   [Full Text] [Related]  

  • 55. Newer drugs in leprosy.
    Grosset JH
    Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2 Suppl):S14-8. PubMed ID: 11757174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Late relapses in leprosy patients in Brazil: 10-year post-trial of uniform multidrug therapy (U-MDT/CT-BR).
    Penna GO; Pontes MAA; Talhari S; Gonçalves HS; Talhari C; Pessoa AS; Pedroza V; Bührer-Sékula S; Stefani MMA; Penna MLF
    Braz J Infect Dis; 2024; 28(2):103745. PubMed ID: 38697216
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rifampicin resistant leprosy: a review and a research proposal of a pilot study.
    Ji B
    Lepr Rev; 2002 Mar; 73(1):2-8. PubMed ID: 11969122
    [No Abstract]   [Full Text] [Related]  

  • 58. Study of rifampicin resistance and comparison of dapsone resistance of M. leprae in pre- and post-MDT era.
    Gupta UD; Katoch K; Katoch VM
    Indian J Lepr; 2009; 81(3):131-4. PubMed ID: 20509341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A overview of ocular leprosy after 2 decades of multidrug therapy.
    Lewallen S; Courtright P
    Int Ophthalmol Clin; 2007; 47(3):87-101. PubMed ID: 17667278
    [No Abstract]   [Full Text] [Related]  

  • 60. Evaluation of multi-drug therapy for leprosy in the United States using daily rifampin.
    Dacso MM; Jacobson RR; Scollard DM; Stryjewska BM; Prestigiacomo JF
    South Med J; 2011 Oct; 104(10):689-94. PubMed ID: 21941157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.